NCT05206812View on ClinicalTrials.gov

Window of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynamics in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

March 31, 2022

Primary Completion Date

May 31, 2023

Study Completion Date

December 31, 2025

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

durvalumab

"* durvalumab 1500 mg QD\*~* Surgery within 1 to 8 weeks - 4 cycles of durvalumab 1500 mg/m2 (Day 1, Day 8)+cisplatin 80 mg/m2 (Day 1) q3wks -durvalumab 1500 mg q4wks (Maximum of 10 cycles)"

Trial Locations (1)

Unknown

Yonsei University Health System, Severance Hospital, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT05206812 - Window of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynamics in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE) | Biotech Hunter | Biotech Hunter